Connect with us


CannTrust (CTST) Stock Drops Over 20% Due to Health Canada Audit’s Non-Licensed Production




A recent audit by Health Canada hit CannTrust Holdings Inc. with a non-compliant rating. This follows the non-licensed sales scandal that crippled Bonify earlier in the year.

This time, Health Canada discovered that CannTrust produced cannabis in five unlicensed rooms of the company’s Pelham grow facility. While these rooms were going through the licensing process, they were yet to be approved. Licensing was eventually given to all the five rooms in April, but unlicensed cannabis cultivation had already gone on for six months since October 2018.

The audit also discovered that the company’s employees purposefully provided inaccurate information to the regulator.

Following the news, CannTrust’s shares dropped by 21% to a price of $3.88 as of Monday afternoon.

Health Canada has since the non-compliant rating complaint been holding 5,200 Kg of the company’s dried flower produced at the Pelham facility. CannTrust is further voluntarily holding 7,200 of product that was produced in non-compliant grow rooms.

Issuing a statement regarding the situation, CannTrust’s Chief Executive Officer said that their team has been focusing on building a culture of trust, transparency, and excellence in all aspects of business including their relations with the regulator. Peter Aceto, the CEO, said that the company has made many changes iron out issues with Health Canada, noting that they have learned lessons and are ready to move forward.

Aceto has since confirmed that some the produce grown in unlicensed rooms has already been shipped out to the market. Although the specific actions to be taken in regards to those shipments remains unclear, the company is as of now in contact with all its provincial distributors to track down where the products were sent.

Aceto also said that all CannTrust’s unlicensed products meet required production and manufacturing safety standards, and had undergone the same quality assessment as any other products produced by the company.

Although Health Canada is expected to take further action, CannTrust is retaining a set of external advisors to review the compliance processes independently.

Michael is a freelance writer with several years of experience in writing of all kinds. From the uber-technical to the more relaxed, he is well-versed in a variety of styles. Lately, his work has been primarily focused on the CBD industry—a market with which he has a particular background and interest. Michael has an extensive interest and experience in legal research for the CBD market, and he has a knack for well-researched pieces and guides for the growing CBD and medicinal cannabis community.

Continue Reading

Ultimate CBD Guide


ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email

Copyright © 2020 | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.